Vertex Pharmaceuticals

“Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals, which develops treatments for endocrine disorders, in a $10 billion deal.”

“Vertex Pharmaceuticals agreed to acquire endocrinology biotech Crinetics Pharmaceuticals for $10b in cash, or $85 per share (102% premium to yesterday's closing price)”

“Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10B in cash — a 102% premium to the prior day's closing price — underscoring sustained appetite for bolt-on endocrinology/rare disease assets”